Sugi Predict

Sugi Predict / Compounds / SCHEMBL742562

SCHEMBL742562

SCHEMBL742562

CN1CCN(Cc2cc[c]cc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 1/20 0.66
▸ LMNA P02545 1/20 0.61
▸ CHKA P35790 6/20 0.58
▸ CA2 P00918 1/20 0.54
▸ NCF1 P14598 1/20 0.54
▸ PRMT6 Q96LA8 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.51
▸ HDAC6 Q9UBN7 1/20 0.50
▸ HRH3 Q9Y5N1 4/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ TP53 P04637 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ SIGMAR1 Q99720 1/20 0.48
▸ HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18227661 0.93 CHKA (0.70) MC4RLMNACHKACA2NCF1
SCHEMBL3140527 0.89 CHKA (0.70) MC4RLMNACHKACA2NCF1
SCHEMBL2475809 0.84 ALDH1A1 (0.63) MC4RLMNANCF1ALDH1A1HRH3
SCHEMBL7356340 0.81 HRH3 (0.60) CHKACA2NCF1PRMT6ALDH1A1
SCHEMBL738784 0.81 HRH3 (0.67) NCF1ALDH1A1HRH3KDM4E
SCHEMBL4137047 0.81 PKM (0.53) MC4RLMNAALDH1A1HRH3NPC1
SCHEMBL27862086 0.80 HRH3 (0.44) MC4RLMNAALDH1A1HRH3NPC1
Hydrochloric Acid SCHEMBL15162706 0.80 MC4R (0.92) MC4RLMNACHKANPC1TP53
SCHEMBL2184615 0.79 SIGMAR1 (0.62) MC4RSIGMAR1
SCHEMBL27808387 0.79 HRH3 (0.51) MC4RALDH1A1HRH3KDM4ESIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11591299-B1 Prodrug compound of levosimendan, preparation method and use thereof Beijing Chenguang Tongchuang Pharmaceutical Research Institute Co., Ltd. (CN) 2023-02-28 — — US claimed
CN-112500353-B Levosimendan prodrug compound, preparation method and application thereof 北京晨光同创医药研究院有限公司 2022-11-25 — — CN claimed
CN-114787160-A Imidazopyridazines and imidazopyridines as activin receptor-like kinase-2 inhibitors 因赛特公司 2022-07-22 — — CN claimed
EP-3898627-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE-2 Incyte Corporation (US) 2021-10-27 — — EP claimed
CN-111777592-B N4- (2, 5-dimethoxyphenyl) -pyrimidinediamine targeted DDR1 inhibitor and preparation and application thereof 温州医科大学 2021-06-18 — — CN claimed
CN-112500353-A Levosimendan prodrug compound, preparation method and application thereof 北京晨光同创医药研究院有限公司 2021-03-16 — — CN claimed
US-20200199131-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-06-25 — — US claimed
WO-2020132197-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE-2 INCYTE CORPORATION (US) 2020-06-25 — — WO claimed
CN-105829308-B Isochromene derivatives as phosphoinositide 3-kinase inhibitors 奇斯药制品公司 2019-03-08 — — CN claimed
US-20180305312-A1 EBNA1 INHIBITORS AND METHODS USING SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-10-25 — — US claimed
CN-1556807-A Chemical compounds �㶫��������ҽҩ�ɷ����޹�˾ 2004-12-22 — — CN claimed
EP-1436291-A2 INDOLIZINES AS KINASE PROTEIN INHIBITORS Aventis Pharma S.A. (FR) 2004-07-14 — — EP claimed
WO-2004056827-A2 SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2004-07-08 — — WO claimed
US-20040102453-A1 N-phenyl-2-pyrimidine-amine derivatives NOVARTIS AG (CH) 2004-05-27 — — US claimed
CN-1473040-A Association and medicinal composition of CB1 receptor antagonist and sibutramin for treating obesity ���ĵ�˹ҩ��ɷ����޹�˾ 2004-02-04 — — CN claimed
EP-1322634-A1 N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES Novartis AG (CH) 2003-07-02 — — EP claimed
WO-2003024967-A2 INDOLIZINES AS KINASE PROTEIN INHIBITORS AVENTIS PHARMA S.A. (FR) 2003-03-27 — — WO claimed
WO-2002022597-A1 N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES NOVARTIS AG (CH) 2002-03-21 — — WO claimed
US-5866583-A Substituted 2,4-diaminopyrimidines HOFFMANN-LA ROCHE INC. (US) 1999-02-02 — — US claimed
US-5756466-A Inhibitors of interleukin-1β converting enzyme VERTEX PHARMACEUTICALS, INC. (US) 1998-05-26 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180305312-A1 EBNA1 INHIBITORS AND METHODS USING SAME MLLT1, EBNA1BP2, MALT1 MC4R 4701/4885LMNA 897/4885CHKA 1159/4885
US-20040102453-A1 N-phenyl-2-pyrimidine-amine derivatives NUDT1, PNP, TYMP MC4R 2330/4885LMNA 2431/4885CHKA 1435/4885
US-20200199131-A1 IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF ALK, ABL2, ACVR2A MC4R 3841/4885LMNA 1644/4885CHKA 874/4885
US-11591299-B1 Prodrug compound of levosimendan, preparation method and use thereof CYP2D6, CYP21A2, CYP2B6 MC4R 2088/4885LMNA 2287/4885CHKA 2522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.